Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Inositol Safety: Clinical Evidences
European Review for Medical and Pharmacological Sciences 2011; 15: 931-936 Inositol safety: clinical evidences G. CARLOMAGNO, V. UNFER AGUNCO Obstetrics & Gynecology Center, Rome (Italy) Abstract. – Myo-inositol is a six carbon ent required by the human cells for the growth cyclitol that contains five equatorial and one axi- and survival in the culture. In humans and other al hydroxyl groups. Myo-inositol has been classi- species, Myo-inositol can be converted to either fied as an insulin sensitizing agent and it is L- or D-chiro-inositol by epimerases. Early stud- commonly used in the treatment of the Polycys- tic Ovary Syndrome (PCOS). However, despite ies showed that inositol urinary clearance was al- its wide clinical use, there is still scarce informa- tered in type 2 diabetes patients, the next step tion on the myo-inositol safety and/or side ef- was to link impaired inositol clearance with in- fects. The aim of the present review was to sum- sulin resistance (for a review see1). Because of marize and discuss available data on the myo-in- these properties, inositol have been classified as ositol safety both in non-clinical and clinical set- “insulin sensitizing agent”2. tings. The main outcome was that only the highest In the recent years, inositol has found more dose of myo-inositol (12 g/day) induced mild and more space in the reproductive clinical prac- gastrointestinal side effects such as nausea, fla- tice3-6. Indeed, since the main therapy for Poly- tus and diarrhea. The severity of side effects did cystic Ovary Syndrome (PCOS) is the use of in- not increase with the dosage. -
Revisions to USP 31–NF 26, Second Supplement
Revisions to USP 31–NF 26, Second Supplement (published May 2008) Published April 2008 General Chapters Monographs:A–C D–N O–S T–Z Monograph Title Section Head Scientific Liaison DANTROLENE SODIUM Dissolution <711> CAPSULES PF 33(4) Pg. 645 DEHYDROACETIC ACID PF 33(4) Title Pg. 703 DEHYDROACETIC ACID PF 33(4) Chemical Info Pg. 703 DEHYDROACETIC ACID PF 33(4) Definition Pg. 703 DEHYDROACETIC ACID PF 33(4) Packaging and storage Pg. 703 DEHYDROACETIC ACID PF 33(4) USP Reference standards <11> Pg. 703 DEHYDROACETIC ACID PF 33(4) Identification Pg. 703 DEHYDROACETIC ACID PF 33(4) Heavy Metals, Method II <231> Pg. 703 DEHYDROACETIC ACID PF 33(4) Loss on drying <731> Pg. 703 DEHYDROACETIC ACID PF 33(4) Melting range, Class I <741> Pg. 703 DEHYDROACETIC ACID PF 33(4) Residue on ignition <281> Pg. 703 DEHYDROACETIC ACID PF 33(4) Assay Pg. 703 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Title 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Definition 784 file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM] DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Packaging and storage 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Labeling 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. USP Reference stadards 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Identification 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Uniformity of dosage units 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Loss on drying 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. -
AP Suspension and Powder
AP Suspension and Powder • Easily application and distribution • Ultrafine surface • Excellent stability Struers AP Suspensions and Powders are based on ultra pure aluminium oxides (alumina). They are available in two forms, Struers ApS deagglomerated and agglomerated. Pederstrupvej 84 DK-2750 Ballerup, Denmark Phone +45 44 600 800 Fax +45 44 600 801 [email protected] www.struers.com AUSTRALIAN & NEW ZEALAND NETHERLANDS Struers Australia Struers GmbH Nederland 27 Mayneview Street Zomerdijk 34 A Milton QLD 4064 3143 CT Maassluis Australia Telefoon +31 (10) 599 7209 Phone +61 7 3512 9600 Fax +31 (10) 5997201 Fax +61 7 3369 8200 [email protected] [email protected] NORWAY BELGIUM (Wallonie) Struers ApS, Norge Deagglomerated Agglomerated Struers S.A.S. Sjøskogenveien 44C 370, rue du Marché Rollay 1407 Vinterbro F- 94507 Champigny Telefon +47 970 94 285 Deagglomerated sur Marne Cedex [email protected] Téléphone +33 1 5509 1430 AP-D, deagglomerated aluminas are premium polishing abrasive and are agglomerate-free. The uniform Télécopie +33 1 5509 1449 AUSTRIA [email protected] Struers GmbH crystals ensure an ultrafine surface. Zweigniederlassung BELGIUM (Flanders) Österreich Struers GmbH Nederland Betriebsgebiet Puch Nord 8 Agglomerated Zomerdijk 34 A 5412 Puch 3143 CT Maassluis Telefon +43 6245 70567 AP-A, agglomerated aluminas are easily broken down during the polishing process while still providing Telefoon +31 (10) 599 7209 Fax +43 6245 70567-78 Fax +31 (10) 5997201 [email protected] faster initial stock removal. [email protected] POLAND CANADA Struers Sp. z o.o. Alumina powders Struers Ltd. Oddział w Polsce 7275 West Credit Avenue ul. Jasnogórska 44 Alumina powders consist of uniform particles with a narrow particle size distribution. -
Phase Behavior and Aggregate Structure in Mixtures of Dioleoylphosphatidylethanolamine and Poly(Ethylene Glycol)-Lipids
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biophysical Journal Volume 80 January 2001 313–323 313 Phase Behavior and Aggregate Structure in Mixtures of Dioleoylphosphatidylethanolamine and Poly(Ethylene Glycol)-Lipids Markus Johnsson and Katarina Edwards Department of Physical Chemistry, Uppsala University, S-751 21 Uppsala, Sweden ABSTRACT Cryo-transmission electron microscopy has been used to investigate the phase behavior and aggregate structure in dilute aqueous mixtures of dioleoylphosphatidylethanolamine (DOPE) and poly(ethylene glycol)-phospholipids (PEG-lipids). It is shown that PEG-lipids (micelle-forming lipids) induce a lamellar phase in mixtures with DOPE (inverted hexagonal forming lipid). The amount of PEG-lipid that is needed to induce a pure dispersed lamellar phase, at physiological conditions, depends on the size of the PEG headgroup. In the transition region between the inverted hexagonal phase and the lamellar phase, particles with dense inner textures are formed. It is proposed that these aggregates constitute dispersed cubic phase particles. Above bilayer saturating concentration of PEG-lipid, small disks and spherical micelles are formed. The stability of DOPE/PEG-lipid liposomes, prepared at high pH, against a rapid drop of the pH was also investigated. It is shown that the density of PEG-lipid in the membrane, sufficient to prevent liposome aggregation and subsequent phase transition, depends on the size of the PEG headgroup. Below a certain density of PEG-lipid, aggregation and phase transition occurs, but the processes involved proceed relatively slow, over the time scale of weeks. This allows detailed studies of the aggregate structure during membrane fusion. -
Genetic Control of Apigenin Di-C-Glycoside Biosynthesis in Bread Wheat Grain and Their Role
Genetic control of Apigenin di-C-glycoside biosynthesis in bread wheat grain and their role as yellow pigments of Asian alkaline noodles Submitted by Grace Yasmein Wijaya This thesis is submitted to Faculty of Sciences in fulfilment of the requirements for the degree Doctor of Philosophy Faculty of Science The University of Adelaide November 2012 This book is An Answer to Prayers of a Long list of Believers I have been very blessed and loved with all of your spiritual supports, for His guidance and protections, and sincerely will not have enough to thank you all..... May you all be blessed and loved, too As I have been always, yasmein Table of Content Table of Content i List of Tables x List of Figures xiii List of Supplemental Materials xxv Summary xxx Statement of Authorship xxxiv List of Publications xxxv Acknowledgement xxxvi List of Abbreviations xxxix Chapter I: General Introduction 1 1.1 Background 1 1.2 Knowledge Gap 2 1.3 Structure of thesis 2 Chapter II: Literature review 4 2.1 Asian noodles as one of the major end-products of Australian bread wheat 4 2.2 Yellow colour of YAN 5 2.2.1 Natural Compounds that contribute to the yellow colour of YAN 5 2.2.1.1 Types of natural compounds that contributes to the yellow colour of YAN and their roles in plants and human health 5 2.2.1.2 Contribution of xanthophylls and ACGs to the yellow colour of alkaline noodles 8 2.2.2 Factors influencing the measurement of the yellowness of noodles and the content of xanthophyll and ACG in wheat grain 10 i 2.2.3 The amount, tissue location and composition -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Inositol (Powder) Introduced 2008
Product Information Sheet – March 2016 Inositol (powder) Introduced 2008 What Is It? Inositol (powder) Inositol is a component of the B-complex family. It supports healthy two scoops (approximately 4.2 g) contain v central nervous system function, including emotional wellness, healthy mood and behavior. Additionally, it may promote ovarian health.* inositol (as myo-inositol) .................................................................................4.2 g serving size: approximately 4.2 g (2 scoops) Uses For Inositol (powder) servings per container: 60 Emotional Wellness: Myo-inositol is the primary form of inositol 2 scoops, 1–2 times daily, with or between meals, or as directed found in the central nervous system. It plays an important role in cell by a health professional. membrane formation and serves as part of the phosphatidylinositol second messenger system, supporting serotonin, norepinenephrine and cholinergic receptor function. As a result, inositol may support healthy mood, emotional wellness and behavior, and ease occasional nervous tension.* Ovarian Function: Research suggests that myo-inositol may help to support healthy ovulatory activity, ovarian function and reproductive system function.* What Is The Source? Myo-inositol is derived from rice bran. Recommendations Pure Encapsulations® recommends 2 scoops, 1–2 times daily, with or between meals, or as directed by a health professional. Are There Any Potential Side Effects Or Precautions? Rarely, inositol has been associated with nausea, fatigue, headache or dizziness. If pregnant or lactating, consult your physician before taking this product. Are There Any Potential Drug Interactions? At this time, there are no known adverse reactions when taken in conjunction with medications. Consult your physician for more information. *These statements have not been evaluated by the Food and Drug Administration. -
WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V. -
Grade 6 Science Mechanical Mixtures Suspensions
Grade 6 Science Week of November 16 – November 20 Heterogeneous Mixtures Mechanical Mixtures Mechanical mixtures have two or more particle types that are not mixed evenly and can be seen as different kinds of matter in the mixture. Obvious examples of mechanical mixtures are chocolate chip cookies, granola and pepperoni pizza. Less obvious examples might be beach sand (various minerals, shells, bacteria, plankton, seaweed and much more) or concrete (sand gravel, cement, water). Mechanical mixtures are all around you all the time. Can you identify any more right now? Suspensions Suspensions are mixtures that have solid or liquid particles scattered around in a liquid or gas. Common examples of suspensions are raw milk, salad dressing, fresh squeezed orange juice and muddy water. If left undisturbed the solids or liquids that are in the suspension may settle out and form layers. You may have seen this layering in salad dressing that you need to shake up before using them. After a rain fall the more dense particles in a mud puddle may settle to the bottom. Milk that is fresh from the cow will naturally separate with the cream rising to the top. Homogenization breaks up the fat molecules of the cream into particles small enough to stay suspended and this stable mixture is now a colloid. We will look at colloids next. Solution, Suspension, and Colloid: https://youtu.be/XEAiLm2zuvc Colloids Colloids: https://youtu.be/MPortFIqgbo Colloids are two phase mixtures. Having two phases means colloids have particles of a solid, liquid or gas dispersed in a continuous phase of another solid, liquid, or gas. -
New Zealand Regulatory Guidelines for Medicines
New Zealand Regulatory Guidelines for Medicines Part G: Resources Edition 6.13 March 2011 (consolidation of fifth edition and subsequent updates) Table of Contents PART G: RESOURCES Section 1: Description of Dosage Form...............................................................................2 Section 2: Routes of Administration....................................................................................4 Section 3: Shelf Life and Storage Conditions .....................................................................5 Section 4: Abbreviations.......................................................................................................6 Description of Dosage Form The dosage form description for a product should be selected from the following list: Block Granules, oral Capsule Implant, subcutaneous Capsule, combination Implant, intracranial Capsule, liquid filled Implant, intraocular Capsule, modified release Infusion, concentrate Capsule, powder filled Infusion, emulsion Capsule, powder filled, nasal inhalation Infusion, powder for Capsule, soft gelatin Infusion, powder for concentrate Cement, bone, liquid component Infusion, solution Cement, bone, powder component Inhalation, capsule, liquid filled Cement, dental Inhalation, capsule, powder filled Chewing gum Inhalation, powder Chocolate, medicated Inhalation, solution Combination Inhalation, solution, powder for Condom, medicated Inhalation, suspension Condom with spermicide Inhalation, volatile liquid Cream, rectal Inhaler, aerosol, metered Cream, topical Injection -
1 090304 Quiz 8 Introduction to Polymers (Chemistry) This Week We
090304 Quiz 8 Introduction to Polymers (Chemistry) This week we ran a suspension polymerization to make polystyrene, a solution polymerization to make polyacrylamide and we discussed Ziegler-Natta polymerization to make polypropylene. 1) Suspension polymerization is similar to emulsion polymerization. a) Describe the importance of water to emulsion and suspension polymerization. Does water play an identical role in these two polymerizations? Is water a solvent? b) Describe the initiator that we used in suspension polymerization. What condition is needed to initiate this reaction? Why was a different initiator used in the emulsion polymerization? c) What is divinyl benzene and why is it included in this reaction? d) What controls the size of the polymer beads (droplet size) that result from suspension polymerization? e) What was the advantage of emulsion polymerization (over suspension polymerization) that lead to its development by Goodyear Tire and Rubber in the 1920’s? 2) Polyacrylamide is soluble in water as is the monomer acrylamide therefore this is a solution polymerization. a) Use the words ferric and ferrous to describe the initiator system for this polymerization. Why is this called a redox system? b) When hydrogen peroxide was added to the reaction mixture it turned from a faint bluish green to red (rust color). Later the color seemed to fade. Why did it change color? c) What temperature was needed to perform this polymerization? Why? d) How was polymer separated from the viscous reaction mixture after polymerization? e) Explain the disadvantage of solution polymerization compared to emulsion or suspension polymerization. 3) We looked at Ziegler-Natta polymerization briefly. -
Instruction Booklet ATTENTION: There Are 3 Critical Steps in the Reconstitution of Sandostatin® LAR
Instruction Booklet ATTENTION: There are 3 critical steps in the reconstitution of Sandostatin® LAR. Not following them could result in failure to deliver the Preparation and Administration of drug appropriately. • The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. • After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum FOR DEEP INTRAGLUTEAL INJECTION ONLY of 2 minutes and up to 5 minutes. Read this entire booklet before proceeding. • After saturation, shake the vial moderately in a If you have questions about preparation and/or administration horizontal direction for a minimum of 30 seconds, until of Sandostatin® LAR Depot, please call 1-888-NOW-NOVA uniform suspension is formed. (1-888-669-6682). Instructions for gluteal Intramuscular (IM) Injection of Step 1 Sandostatin® LAR Depot (octreotide acetate) for injectable suspension • Remove the Sandostatin® LAR injection kit from Important Information for Health Care Professionals refrigerated storage. Successful preparation and administration ATTENTION: It is essential to start of Sandostatin® LAR Depot relies on proper the reconstitution process only after suspension technique. the injection kit has reached room Follow each of the steps outlined in this instruction booklet temperature. Let the kit stand to ensure complete saturation of the powder and its uniform at room temperature for a minimum suspension prior to deep intragluteal injection. of 30 minutes before reconstitution, but do not exceed 24 hours. It is critical that Sandostatin® LAR Depot and the diluent be allowed to reach room temperature and then be mixed Note: The injection kit can be re-refrigerated if needed.